Back to search
ALK Fusion-positive Solid or CNS Tumors
Clinical trial pipeline · Data from ClinicalTrials.gov
See which ALK Fusion-positive Solid or CNS Tumors trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which ALK Fusion-positive Solid or CNS Tumors trials you may qualify forCurrently, tyrosine kinase inhibitor (TKI) remains the standard of care for oncogene-driven non-small cell lung cancer (NSCLC). However, almost all oncogene-dri…
This study will evaluate the efficacy and safety of alectinib in participants with Anaplastic Lymphoma Kinase (ALK)-positive locally advanced or metastatic soli…
This phase II trial studies how well brigatinib works in treating patients with ALK and ROS1 gene alterations and solid cancers that have spread to nearby tissu…